Cargando…

Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A

Patients with the severe form of hemophilia A (HA) present with a severe phenotype, and can suffer from life-threatening, spontaneous hemorrhaging. While prophylactic FVIII infusions have revolutionized the clinical management of HA, this treatment is short-lived, expensive, and it is not available...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stem, Christopher, Rodman, Christopher, Ramamurthy, Ritu M., George, Sunil, Meares, Diane, Farland, Andrew, Atala, Anthony, Doering, Christopher B., Spencer, H. Trent, Porada, Christopher D., Almeida-Porada, Graça
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cell and Developmental Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383113/ https://www.ncbi.nlm.nih.gov/pubmed/34447745 http://dx.doi.org/10.3389/fcell.2021.678117

Ejemplares similares

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
por: El-Akabawy, Nadia, et al.
Publicado: (2020)

Hemophilia A: an ideal disease to correct in utero
por: Porada, Christopher D., et al.
Publicado: (2014)

Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A
por: Trevisan, Brady, et al.
Publicado: (2021)

Development and Characterization of Recombinant Ovine Coagulation Factor VIII
por: Zakas, Philip M., et al.
Publicado: (2012)

Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII
por: Ramamurthy, Ritu M., et al.
Publicado: (2022)

Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity
por: Rodriguez, Martin, et al.
Publicado: (2023)

Organoids and microphysiological systems: Promising models for accelerating AAV gene therapy studies
por: Ramamurthy, Ritu Mahesh, et al.
Publicado: (2022)

In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application
por: Almeida-Porada, Graça, et al.
Publicado: (2016)

Therapeutic Mesenchymal Stromal Cells for Immunotherapy and for Gene and Drug Delivery
por: Almeida-Porada, Graça, et al.
Publicado: (2020)

Autologous bone marrow-derived MSCs engineered to express oFVIII-FLAG engraft in adult sheep and produce an effective increase in plasma FVIII levels
por: Trevisan, Brady, et al.
Publicado: (2022)

Generation of an Optimized Lentiviral Vector Encoding a High-Expression Factor VIII Transgene for Gene Therapy of Hemophilia A
por: Johnston, Jennifer M., et al.
Publicado: (2012)

Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice
por: Lundgren, Taran S., et al.
Publicado: (2022)

Boosting Hematopoietic Engraftment after in Utero Transplantation through Vascular Niche Manipulation
por: Mokhtari, Saloomeh, et al.
Publicado: (2016)

Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII
por: Russell, Athena L., et al.
Publicado: (2021)

The Immune Response to the fVIII Gene Therapy in Preclinical Models
por: Patel, Seema R., et al.
Publicado: (2020)

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery
por: Brown, Harrison C, et al.
Publicado: (2014)

Potentiation of Thrombin Generation in Hemophilia A Plasma by Coagulation Factor VIII and Characterization of Antibody-Specific Inhibition
por: Doshi, Bhavya S., et al.
Publicado: (2012)

A HUMAN BONE MARROW MESODERMAL-DERIVED CELL POPULATION WITH HEMOGENIC POTENTIAL
por: Mokhtari, Saloomeh, et al.
Publicado: (2018)

Evaluation of gene delivery strategies to efficiently overexpress functional HLA-G on human bone marrow stromal cells
por: Boura, Joana S, et al.
Publicado: (2014)

The effect of low-frequency electromagnetic field on human bone marrow stem/progenitor cell differentiation
por: Ross, Christina L., et al.
Publicado: (2015)

Target-Cell-Directed Bioengineering Approaches for Gene Therapy of Hemophilia A
por: Brown, Harrison C., et al.
Publicado: (2018)

Mesenchymal Stem Cells Engineered to Inhibit Complement-Mediated Damage
por: Soland, Melisa A., et al.
Publicado: (2013)

Modulation of Human Mesenchymal Stem Cell Immunogenicity through Forced Expression of Human Cytomegalovirus US Proteins
por: Soland, Melisa A., et al.
Publicado: (2012)

Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A
por: Lytle, Allison M, et al.
Publicado: (2016)

Characterization of Naturally-Occurring Humoral Immunity to AAV in Sheep
por: Tellez, Joseph, et al.
Publicado: (2013)

Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor
por: Ronayne, Estelle K., et al.
Publicado: (2021)

Evaluating Interaction of Cord Blood Hematopoietic Stem/Progenitor Cells with Functionally Integrated Three‐Dimensional Microenvironments
por: Mokhtari, Saloomeh, et al.
Publicado: (2018)

Chemical Chaperones Improve Protein Secretion and Rescue Mutant Factor VIII in Mice with Hemophilia A
por: Roth, Stefanie D., et al.
Publicado: (2012)

Curcumin Nanodiscs Improve Solubility and Serve as Radiological Protectants against Ionizing Radiation Exposures in a Cell-Cycle Dependent Manner
por: Evans, Angela C., et al.
Publicado: (2022)

Targeting Mesenchymal Stromal Cells/Pericytes (MSCs) With Pulsed Electromagnetic Field (PEMF) Has the Potential to Treat Rheumatoid Arthritis
por: Ross, Christina L., et al.
Publicado: (2019)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
por: Karakuş, Volkan, et al.
Publicado: (2012)

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
por: Abt, Nicholas B., et al.
Publicado: (2014)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017)

Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
por: Khalilian, Sheyda, et al.
Publicado: (2020)

Evaluation of Cytotoxic and Genotoxic Effects of Extremely Low-frequency Electromagnetic Field on Mesenchymal Stromal Cells
por: Ross, Christina L, et al.
Publicado: (2018)

Antiguo Irán
por: Porada, Edith, 1912-
Publicado: (1963)

Measuring the Impact of Epidemic Outbreaks on Financial Results
por: Rochoń, Małgorzata Porada
Publicado: (2021)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ms05e23io8madtc0ugsgv0h042